More Videos
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Merck Offering To Help Patients—Or Itself?
- GM, Ford & Chrysler CEOs Take Their Medicine
- Daschle's Dollars From Lawyers, Not Pharma
- AstraZeneca Provides Zest and Zeal For OSI Pharmaceuticals
- Novo Nordisk "Raises" Price On Treating Diabetes
- Carl Icahn: Can He Come To Amylin's Rescue?
- Merck Rolls The Dice On Januvia
- Merck's Marketing Challenge: Gardasil For Guys
- Pharma And The Financial Crisis
- Out with Cox, in with Uptick Rule
- Pops & Drops: Hewlett-Packard, JP Morgan & Air Wagoner
- Mad Money Green Week: Owens Corning
- Fast & Furious: It's All About Soup
- Web Extra: The Trade on Walmart and RIMM
- Chartology: Grossly Oversold and Favoring the Upside
- The "Armageddon" Gameplan
- What's Next for Citigroup?
- What to Expect From a Geithner-led Treasury
- Citigroup Update: Reports Emerge Of Possible Plan
- Saudi Arabia Forced To Slash Interest Cuts By Crisis
- Asia-Pacific Summit Continues Drumbeat Of Economic Woes
- Global Markets Want Catalysts For Buying This Week
- Economic Team Obama: Will It Help Settle Markets?
- American, Asian Leaders Push Free Trade To End Crisis
- Citigroup Update: Reports Emerge Of Possible Plan
- Soros: More Money Needed For U.S. Bailout
- HP Earnings: How Much Will "Hurt" From Economy?
Text Size 
 |
New York Post/Robert Kalfus Insider trader Sam Waksal, toting a bag from Smythson, a luxury leather shop. |
Two Post reporters also worked the story of the former ImClone Systems CEO's first few days out of federal prison after I blogged late last week that CNBC confirmed Waksal had returned to New York.
The Post says Waksal is getting preferential treatment at the halfway house, which also let him go free from Friday through Sunday. Did anyone out there spot him at some old haunts in his Hamptons stomping grounds? I'm not certain if he can leave the confines of the New York boroughs. And I don't think he can hang out with another ex-con like his old friend Martha Stewart.
He also can't go near Manhattan-based ImClone [IMCL
Loading...
()
]. Not physically, but fiscally.
Shares of the company he founded are still trading about $4 higher than the price Bristol-Myers Squibb [BMY
Loading...
()
] has offered to buy the rest of the company it doesn't already own. The two are partners on the cancer drug Erbitux.
In a research note to clients this morning, Leerink Swann big pharma analyst Seamus Fernandez writes that he wouldn't be surprised to see the ultimate takeout price around 70 bucks. For now, though, Bristol officials insist their offer is "full and fair."
Fernandez also breaks down the projected negative impact the different prices will have on BMY's earnings, but how the hit might be absorbed by so-called synergies -- M&A-speak for cost-cutting. Finally, he sees U.S. Erbitux sales growing at a compounded annual growth rate of 23 percent, from $825 million this year to $1.8 billion in 2012.
Disclosures:
Leerink Swann makes a market in IMCL and may trade in BMY.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes